Generic drug makers Teva Pharmaceutical Industries and Dr Reddy’s Laboratories have announced the commercial launch of olanzapine tablets, a generic version of Eli Lilly antipsychotic Zyprexa.

Teva will introduce tablets in 2.5mg, 5mg, 7.5mg, 10mg, 15mg doses, while Dr Reddy’s will introduce a 20mg tablet. Both companies have been granted a 180-day period of marketing exclusivity in the US for their respective tablets.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Dr Reddy’s is supplying the 20mg version of the product as part of a commercialisation, manufacture and supply agreement agreed in April 2011.

In addition, Dr Reddy’s will launch its 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg olanzapine tablets upon expiration of the 180-day exclusivity period.

Annual sales of Zyprexa in the US stood at approximately $3.2bn as of September 2011.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now